Avadel Pharmaceuticals plc
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
About
CEO
Mr. Gregory J. Divis Jr.
Employees
154
Instrument type
Depositary Receipt
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
MIC code
XNMS
Address
10 Earlsfort Terrace, Dublin, 2, Ireland
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 10, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Mar 3, 2025 | — | — | — | — |
| Nov 12, 2024 | -0.06 | -0.03 | 0.03 | -50.00% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 3 |
| Average estimate | — | -0.05 | — | 0.16 |
| Low estimate | — | -0.07 | — | 0.10 |
| High estimate | — | -0.02 | — | 0.19 |
| Last year EPS | — | -0.30 | — | -0.49 |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
86.670%
Current year
—
Next year (Dec 2025)
131.290%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 27.96M | — | — | 22.33M | 59.22M |
| Cost of revenue | 846,000 | — | — | 5.74M | 12.13M |
| Gross profit | 27.12M | — | — | 16.59M | 47.09M |
| Operating expense | |||||
| Research & development | 13.26M | 20.70M | 17.10M | 20.44M | 32.92M |
| Selling general and admin | 151.71M | 74.52M | 68.50M | 32.41M | 30.18M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -137.85M | -95.22M | -85.60M | -36.66M | -16.83M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 9.89M | 12.34M | 9.94M | 12.99M | 12.48M |
| Other income expense | -13.04M | -3.88M | 2.40M | 44.57M | -9.27M |
| Pretax income | -160.78M | -111.44M | -93.15M | -5.08M | -38.58M |
| Tax provision | -501,000 | 26.03M | -15.82M | -12.11M | -5.36M |
| Net income | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M |
| Basic EPS | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 |
| Diluted EPS | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 |
| Basic average shares | 80.17M | 60.09M | 58.54M | 53.00M | 37.40M |
| Diluted average shares | 80.17M | 60.09M | 58.54M | 53.00M | 37.40M |
| EBITDA | -136.08M | -93.72M | -84.78M | -31.61M | -14.34M |
| Net income from continuing op. | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 164.70M | 132.79M | 247.27M | 311.64M | 151.44M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 31.17M | 73.98M | 50.71M | 71.72M | 9.77M |
| Other short term investments | 73.94M | 22.52M | 106.51M | 149.68M | 54.38M |
| Accounts receivable | 12.10M | — | — | — | 8.28M |
| Other receivables | — | — | — | 16.50M | — |
| Inventory | 10.38M | — | — | — | 3.57M |
| Prepaid assets | 4.37M | 1.52M | 3.18M | 2.50M | 2.12M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 913,000 | 573,000 | 550,000 | 1.12M | 561,000 |
| Non current assets | |||||
| Properties | 12.50M | 12.40M | 11.20M | 7.81M | 10.04M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 1.47M | 1.47M | 750,000 | 1.74M | 1.56M |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -881,000 | -627,000 | -465,000 | -1.38M | -1.01M |
| Goodwill | 33.67M | 33.67M | 33.67M | 33.67M | 37.80M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | 813,000 |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 579,000 | 1.87M | 26.45M | 23.18M | 37.69M |
| Total liabilities | 76.96M | 153.93M | 169.02M | 149.37M | 180.64M |
| Current liabilities | |||||
| Accounts payable | 11.43M | 7.89M | 7.68M | 2.93M | 6.10M |
| Accrued expenses | 11.96M | 7.37M | 8.90M | 7.50M | 18.56M |
| Short term debt | 934,000 | 38.63M | 900,000 | 474,000 | 645,000 |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 7.49M | 1.61M | 3.17M | 1.70M | 3.94M |
| Other current liabilities | 261,000 | 292,000 | 350,000 | 479,000 | 1.18M |
| Non current liabilities | |||||
| Long term debt | 1.69M | 92.39M | 144.10M | 130.05M | 124.01M |
| Provision for risks and charges | 5.41M | 5.25M | — | — | 11.77M |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 33.01M | 497,000 | 3.92M | 4.21M | 7.89M |
| Shareholders equity | |||||
| Common stock | 898,000 | 628,000 | 586,000 | 583,000 | 429,000 |
| Retained earnings | -745.50M | -585.22M | -447.76M | -384.19M | -391.22M |
| Other shareholders equity | -23.17M | -26.34M | -23.94M | -21.05M | -22.81M |
| Total shareholders equity | 87.74M | -21.15M | 78.24M | 162.27M | -29.20M |
| Additional paid in capital | 855.45M | 589.78M | 549.35M | 566.92M | 434.39M |
| Treasury stock | — | — | — | — | 50.00M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||||
| Net Income | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M | -95.30M | 68.27M | -41.28M | 41.80M | -85.47M | -42.93M | -3.23M | -8.77M | -8.98M | -11.44M | -12.08M | -37.74M | -35.20M | -27.38M | 12.50M | -3.92M | 3.01M | -2.87M | -9.46M | -6.69M | -7.81M | -6.80M | -6.90M |
| Depreciation | 1.77M | 1.49M | 815,000 | 1.69M | 2.49M | 7.43M | 4.88M | 14.49M | 13.13M | 14.14M | 3.06M | 3.18M | 3.35M | 4.70M | 5.92M | 7.25M | 6.20M | 5.64M | 4.74M | 2.53M | 1.71M | 1.46M | 1.27M | 1.11M | 1.21M | 1.04M | 700,000 | 900,000 |
| Deferred Taxes | — | 26.03M | -15.67M | -7.43M | -6.33M | -19.15M | 3.56M | -4.00M | 69,000 | -2.11M | -11.32M | -4.76M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 15.81M | 7.01M | 8.87M | 3.00M | 519,000 | 7.85M | 8.07M | 14.68M | 7.74M | 2.69M | 2.03M | 3.04M | 2.78M | 3.17M | 5.50M | 8.29M | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 4.06M | 8.09M | 2.30M | 875,000 | -5.77M | -37.92M | -70.14M | 32.78M | 34.34M | 63.23M | 30.16M | -19.81M | -3.23M | -884,000 | 5.50M | 8.29M | 11.69M | 10.00M | 546,000 | 1.61M | -195,000 | — | — | — | — | — | — | — |
| Accounts Receivable | -10.22M | 30,000 | 2.80M | 10.49M | 1.46M | 907,000 | -87,000 | -9.65M | -5.47M | 16.46M | 154,000 | -4.03M | -4.40M | 1.57M | 2.81M | -3.89M | -481,000 | -3.95M | 4.77M | 532,000 | -4.03M | 5.96M | -5.18M | -1.14M | 1.21M | 263,000 | -2.50M | -500,000 |
| Accounts Payable | 1.55M | -3.11M | 4.23M | -2.79M | 4.64M | -2.03M | 595,000 | -434,000 | -8.53M | 7.22M | 800,000 | -613,000 | -825,000 | -450,000 | 32,000 | -258,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -8.09M | -3.43M | -3.79M | -4.48M | -3.02M | -3.52M | -7.88M | -557,000 | 7.10M | -6.77M | -4.69M | -4.11M | 467,000 | -4.68M | 9.32M | -5.90M | 3.32M | -1.57M | -2.66M | -21.73M | 34.53M | -1.61M | 4.16M | 3.45M | 727,000 | -1.73M | -300,000 | -2.00M |
| Operating Cash Flow | -155.41M | -101.35M | -77.77M | 8.39M | -39.25M | -141.74M | 7.27M | 6.03M | 90.18M | 9.39M | -22.73M | -30.32M | -10.64M | -5.56M | 17.64M | 1.69M | -17.02M | -25.08M | -19.98M | -4.56M | 28.09M | 8.82M | -2.63M | -6.04M | -3.55M | -8.23M | -8.90M | -8.50M |
| Investing Activities | ||||||||||||||||||||||||||||
| Capital Expenditures | — | -716,000 | -26,000 | -98,000 | 125,000 | -178,000 | -591,000 | -1.20M | -1.63M | 11.51M | -22,000 | -1.00M | -1.72M | -3.47M | -1.77M | -3.52M | -11.23M | -6.30M | -11.17M | -13.29M | -1.92M | -1.43M | -1.18M | -737,000 | -666,000 | -1.13M | -1.60M | -1.50M |
| Net Intangibles | — | — | — | — | — | -20.00M | -53.11M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | 16.50M | 25.50M | — | — | — | 628,000 | — | — | — | 1.77M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -237.23M | -3.41M | -61.77M | -131.41M | -24.65M | -376.31M | -151.01M | -107.60M | -78.41M | -79.59M | -1.09M | -3.57M | -25.02M | -73.63M | -160.97M | -70.78M | -96.71M | -183.61M | -424.38M | -22.57M | -105.29M | — | — | — | — | -4.24M | — | — |
| Sale of Investments | 187.14M | 83.83M | 102.22M | 36.28M | 63.25M | 359.51M | 189.01M | 71.55M | 48.31M | 24.99M | 7.15M | 18.25M | 26.38M | 83.13M | 138.48M | 75.22M | 94.71M | 262.58M | 431.06M | 37.95M | 24.37M | — | — | — | — | — | — | — |
| Investing Cash Flow | -50.09M | 79.70M | 56.93M | -69.72M | 38.72M | -16.98M | 37.41M | -36.63M | -31.73M | -43.08M | 6.05M | 15.45M | -351,000 | 6.03M | -24.26M | 911,000 | -13.23M | 72.67M | -4.50M | 2.08M | -82.85M | -1.43M | -1.18M | -737,000 | 3.39M | 1.41M | -1.60M | -9.30M |
| Financing Activities | ||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | 143.75M | — | — | — | — | 19.33M | 6.67M | 7.86M | 436,000 | 2.19M | 8.61M | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -21.17M | — | — | — | — | — | — | — | -4.91M | -34.35M | -77,000 | -320,000 | -2.01M | -1.91M | -67,000 | -272,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | 8.14M | -13.46M | — | — | -145,000 | -6.94M | -1.36M | -8.39M | -25.83M | -1.92M | -1.38M | — | — | -1.88M | -4.00M | — | — | 2.94M | 4.36M | 3.88M | -997,000 | — | — | — | — | — | -100,000 | 100,000 |
| Financing Cash Flow | 133.04M | 11.86M | — | 179.68M | -27,000 | 109.75M | -23.32M | -7.95M | -23.75M | 96.00M | 18.27M | 6.96M | 6.15M | -2.65M | -1.58M | 8.88M | 569,000 | 5.55M | 18.01M | 4.64M | 73.59M | 1,000 | — | 11.73M | — | 10.19M | 600,000 | 28.60M |
| Other Cash Details | ||||||||||||||||||||||||||||
| End Cash Position | 31.17M | 73.98M | 50.71M | 71.72M | 9.77M | 9.33M | 16.56M | 39.22M | 65.06M | 39.76M | 6.64M | 2.74M | 3.46M | 8.18M | 8.72M | 27.02M | 26.31M | 51.83M | 1.02M | 4.59M | 1.20M | 14.53M | 5.31M | 10.14M | 5.21M | 7.28M | — | — |
| Income Tax Paid | — | — | 76,000 | — | 140,000 | 776,000 | 19.14M | 27.18M | 42.12M | 403,000 | 153,000 | 56,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 5.25M | 9.66M | 6.47M | 6.47M | 6.47M | 3.36M | 1.05M | 788,000 | 4.74M | 4.43M | 1.70M | 118,000 | 73,000 | 24,000 | 100,000 | 18,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -128.51M | -71.02M | -77.34M | -48.83M | -38.35M | -102.89M | -37.04M | 17.70M | 82.66M | -12.35M | -21.71M | -24.21M | -12.23M | -9.06M | 6.43M | -11.03M | -30.51M | -36.22M | -30.72M | -17.99M | 8.63M | 7.34M | -3.96M | -6.36M | -4.91M | -9.32M | -10.50M | -5.70M |
Error: Invalid format in Holders JSON file.
Article
ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors
CHESTERFIELD, Mo.--(BUSINESS WIRE)--The following is a letter that ASL Strategic Value Fund sent to the Board of Directors of Avadel Pharmaceuticals (NASDAQ:AVDL): February 10, 2025 Mr. Geoff Glass Chairman, Board of Directors Avadel Pharmaceuticals Plc 16640 Chesterfield Grove Road, Suite 200 Chesterfield, Mo 63005 Dear Geoff: As you are aware, the ASL Strategic Value Fund has been a long-term investor in Avadel Pharmaceuticals. Our ownership predates most of the directors on the current Board.
Feb 10, 2025
Article
There May Still Be Time to Get in on These 3 Trending Biotechs
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms.
Jan 20, 2025
Article
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels.
Jan 13, 2025
